Bank of America
NKTR icon

Bank of America’s Nektar Therapeutics NKTR Stock Holding History

Bank of America’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24M Buy
58,958
+32,866
+126% +$1.87M ﹤0.01% 3594
2025
Q4 		$1.1M Sell
26,092
-21,867
-46% -$1.22M ﹤0.01% 4469
2025
Q3 		$2.73M Sell
47,959
-19,602
-29% -$649K ﹤0.01% 4546
2025
Q2 		$1.75M Buy
67,561
+59,146
+703% +$664K ﹤0.01% 4892
2025
Q1 		$85.8K Sell
8,415
-5,403
-39% -$70.6K ﹤0.01% 6558
2024
Q4 		$193K Sell
13,818
-733
-5% -$12.9K ﹤0.01% 6140
2024
Q3 		$284K Buy
14,551
+2,415
+20% +$46K ﹤0.01% 5840
2024
Q2 		$226K Buy
12,136
+9,320
+331% +$196K ﹤0.01% 5822
2024
Q1 		$39.5K Sell
2,816
-7,874
-74% -$82.4K ﹤0.01% 6590
2023
Q4 		$90.6K Sell
10,690
-5,763
-35% -$43.6K ﹤0.01% 6410
2023
Q3 		$147K Buy
16,453
+4,496
+38% +$43.3K ﹤0.01% 6075
2023
Q2 		$103K Sell
11,957
-5,215
-30% -$55.6K ﹤0.01% 6191
2023
Q1 		$181K Buy
17,172
+4,021
+31% +$122K ﹤0.01% 5976
2022
Q4 		$446K Sell
13,151
-11,833
-47% -$573K ﹤0.01% 5470
2022
Q3 		$1.2M Buy
24,984
+3,371
+16% +$201K ﹤0.01% 4740
2022
Q2 		$1.23M Buy
21,613
+17,329
+405% +$1.09M ﹤0.01% 4722
2022
Q1 		$346K Sell
4,284
-3,884
-48% -$575K ﹤0.01% 6077
2021
Q4 		$1.66M Sell
8,168
-3,450
-30% -$748K ﹤0.01% 4750
2021
Q3 		$3.13M Buy
11,618
+2,893
+33% +$696K ﹤0.01% 4029
2021
Q2 		$2.25M Buy
8,725
+1,233
+16% +$341K ﹤0.01% 4222
2021
Q1 		$2.25M Buy
7,492
+486
+7% +$151K ﹤0.01% 4163
2020
Q4 		$1.79M Sell
7,006
-489
-7% -$126K ﹤0.01% 4047
2020
Q3 		$1.87M Sell
7,495
-2,603
-26% -$819K ﹤0.01% 3734
2020
Q2 		$3.51M Sell
10,098
-2,491
-20% -$777K ﹤0.01% 3167
2020
Q1 		$3.37M Buy
12,589
+1,298
+11% +$401K ﹤0.01% 3047
2019
Q4 		$3.66M Sell
11,291
-10,345
-48% -$3M ﹤0.01% 3526
2019
Q3 		$5.91M Buy
21,636
+817
+4% +$300K ﹤0.01% 3037
2019
Q2 		$11.1M Buy
20,819
+7,615
+58% +$3.82M ﹤0.01% 2443
2019
Q1 		$6.65M Buy
13,204
+1,764
+15% +$1.05M ﹤0.01% 2877
2018
Q4 		$5.64M Sell
11,440
-1,496
-12% -$903K ﹤0.01% 2863
2018
Q3 		$11.8M Sell
12,936
-5,640
-30% -$4.81M ﹤0.01% 2326
2018
Q2 		$13.6M Sell
18,576
-48,558
-72% -$56M ﹤0.01% 2141
2018
Q1 		$107M Buy
67,134
+41,548
+162% +$53.5M 0.02% 683
2017
Q4 		$22.9M Sell
25,586
-10,794
-30% -$6.38M ﹤0.01% 1700
2017
Q3 		$13.1M Buy
36,380
+9,475
+35% +$2.96M ﹤0.01% 2242
2017
Q2 		$7.89M Buy
26,905
+8,462
+46% +$2.45M ﹤0.01% 2608
2017
Q1 		$6.49M Buy
18,443
+9,222
+100% +$2.07M ﹤0.01% 2788
2016
Q4 		$1.7M Buy
9,221
+7,739
+522% +$1.57M ﹤0.01% 3900
2016
Q3 		$382K Sell
1,482
-159
-10% -$40.9K ﹤0.01% 4798
2016
Q2 		$350K Buy
1,641
+859
+110% +$192K ﹤0.01% 4890
2016
Q1 		$161K Sell
782
-4,193
-84% -$805K ﹤0.01% 5251
2015
Q4 		$1.26M Buy
4,975
+2,376
+91% +$489K ﹤0.01% 4197
2015
Q3 		$426K Sell
2,599
-7,003
-73% -$1.24M ﹤0.01% 4907
2015
Q2 		$1.8M Buy
9,602
+9,114
+1,868% +$1.57M ﹤0.01% 3582
2015
Q1 		$80K Buy
488
+19
+4% +$3.9K ﹤0.01% 5425
2014
Q4 		$110K Sell
469
-1,631
-78% -$349K ﹤0.01% 5807
2014
Q3 		$380K Buy
2,100
+1,622
+339% +$310K ﹤0.01% 4835
2014
Q2 		$92K Sell
478
-724
-60% -$128K ﹤0.01% 6209
2014
Q1 		$219K Sell
1,202
-978
-45% -$194K ﹤0.01% 5361
2013
Q4 		$372K Buy
2,180
+80
+4% +$12.9K ﹤0.01% 5032
2013
Q3 		$329K Sell
2,100
-2,091
-50% -$387K ﹤0.01% 5002
2013
Q2 		$726K Buy
+4,191
New +$643K ﹤0.01% 4370

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America's NKTR Position: Q1 2026 in Review

Bank of America increased its Nektar Therapeutics (NKTR) stake by 126% in Q1 2026, buying an estimated $1.87M and bringing the position to 58,958 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

Bank of America first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $107M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Bank of America held 58,958 shares of Nektar Therapeutics worth $4.24M as of Q1 2026.
  • Bank of America bought 32,866 Nektar Therapeutics shares in Q1 2026, an estimated $1.87M.
  • Nektar Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3594 holding.
  • Bank of America first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Nektar Therapeutics position peaked at $107M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.